India’s Piramal Healthcare has agreed to acquire Bayer HealthCare Pharmaceuticals’ molecular imaging portfolio, including the Alzheimer’s disease diagnostic florbetaben, which will be filed for US FDA approval later in 2012 and which will compete with Eli Lilly’s recently approved Amyvid™ (florbetapir F 18) in detecting cerebral beta-amyloid plaques. Piramal’s newly created Piramal Imaging subsidiary will focus on developing the portfolio.